Wolff Wiese Magana’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$140K Hold
831
0.06% 139
2026
Q1
$109K Hold
831
0.06% 147
2025
Q4
$118K Sell
831
-13
-2% -$1.88K 0.06% 144
2025
Q3
$118K Hold
844
0.07% 140
2025
Q2
$106K Buy
844
+766
+982% +$87.8K 0.07% 141
2025
Q1
$8.63K Sell
78
-25
-24% -$3.17K 0.01% 437
2024
Q4
$14.1K Hold
103
0.01% 357
2024
Q3
$11.9K Buy
103
+56
+119% +$7.68K 0.01% 411
2024
Q2
$6.47K Sell
47
-26
-36% -$3.57K 0.01% 385
2024
Q1
$10.1K Buy
73
+26
+55% +$3.55K 0.01% 296
2023
Q4
$6.19K Hold
47
0.01% 350
2023
Q3
$5.29K Sell
47
-100
-68% -$10.5K ﹤0.01% 428
2023
Q2
$13.9K Hold
147
0.01% 313
2023
Q1
$14.9K Hold
147
0.01% 308
2022
Q4
$17.6K Hold
147
0.02% 272
2022
Q3
$16K Hold
147
0.01% 421
2022
Q2
$14K Hold
147
0.01% 480
2022
Q1
$14K Hold
147
0.01% 492
2021
Q4
$13K Hold
147
0.01% 500
2021
Q3
$14K Hold
147
0.01% 477
2021
Q2
$14K Hold
147
0.01% 448
2021
Q1
$14K Buy
147
+25
+20% +$2.62K 0.01% 435
2020
Q4
$12K Buy
+122
New +$11.8K 0.01% 423

Other funds holding NBIX

Wolff Wiese Magana's NBIX Position: Q2 2026 in Review

Wolff Wiese Magana held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 831 shares worth $140K. The position accounts for 0.06% of the portfolio, ranked #139.

Wolff Wiese Magana first reported a position in NBIX in Q4 2020 and has held it in 23 quarters since. 166 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Wolff Wiese Magana held 831 shares of Neurocrine Biosciences worth $140K as of Q2 2026.
  • Wolff Wiese Magana left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up 0.06% of Wolff Wiese Magana's portfolio in Q2 2026, its #139 holding.
  • Wolff Wiese Magana first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 23 quarters since.
  • 166 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Wolff Wiese Magana's 13F filing for Q2 2026, filed 13 Jul 2026.